Peptide side effects: what trials, labels and safety alerts show

What is the risk of taking peptides?

FDA says “all medicines, both prescription and over-the-counter, have risks as well as benefits”³. It considers a medicine safe enough to approve when its benefits outweigh its known risks³. How much is known about a peptide’s risks depends mainly on whether it is an approved drug¹.

A 2026 review of peptides for injuries and sport draws that line¹. Many peptide drugs have passed “a rigorous approval process that evaluates both safety and efficacy”¹. Beside them, a “gray market” of unapproved compounds operates largely outside regulatory oversight, with “potential for serious harm to patients”¹.

Health Canada’s 9 April 2026 alert on unauthorized injectable peptides lists the risks it sees².

• Effects on the body: “hormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots, and growth of cancerous tumours”².
• Wrong contents: too much, too little or none of the active ingredient, or unlisted, dangerous or unknown ingredients².
• Contamination: solvents, heavy metals, particles such as fibers, glass or plastic, and microbial matter such as bacteria, fungi or endotoxins².
• Poor quality control: products may be poorly or incorrectly labeled, or improperly made or stored².
• Problems from use: infections, allergic reactions and other serious complications, and interactions with other medicines or health products².
• No checks: such products “have not been assessed for safety, efficacy, and quality by Health Canada”².

Which peptide is safest has no single answer, because no medicine is free of risk³. Risk depends on the molecule, on the product and on how it is injected, and the sections below take each in turn¹². Our peptide therapy guide gives a shorter overview, and What are peptides? explains the basics. Our skincare guide covers the downsides of peptide creams and serums.

Are peptide shots like Ozempic?

Ozempic is a peptide shot: semaglutide, its active ingredient, is a modified version of GLP-1, a gut hormone that helps control blood sugar and appetite²³²⁵. Novo Nordisk sells semaglutide as a weekly injection or daily tablet: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight loss²³²⁶²⁷. A 2025 review says synthetic peptides made up over 11% of the new chemical drugs FDA authorized from 2016 to 2024⁴.

What sets approved shots apart is the testing behind them¹. SELECT, semaglutide’s heart trial paid for by Novo Nordisk, followed 17,604 adults with cardiovascular disease and overweight or obesity for a mean of 39.8 months⁵. In it, 16.6% stopped the drug for good because of adverse events (health problems that arise during treatment), versus 8.2% on placebo⁵. For ipamorelin, FDA found no safety data for injections under the skin, one of the ways people use it²⁸.

Semaglutide made outside the approved brands brings other risks: FDA had received 990 adverse event reports for compounded (pharmacy-made) semaglutide as of 31 May 2026²⁹. FDA says such events are likely underreported²⁹. It also warns that counterfeit Ozempic may contain the wrong ingredients, or too little, too much or none of the active one²⁹. Our semaglutide page lists the label’s warnings, and semaglutide vs tirzepatide sets them side by side.

What does taking peptide injections do?

It depends on the peptide, because each acts on its own targets in the body²⁴³⁰³¹. Whether these effects add up to real benefits is covered in our peptide therapy guide.

• GLP-1 drugs: tirzepatide acts on the receptors for two gut hormones, GIP and GLP-1²⁴. It lowers calorie intake, boosts insulin release when blood sugar is raised, lowers glucagon and slows stomach emptying²⁴. Semaglutide stays in the blood for about 5 to 7 weeks after the last dose²³.
• Growth hormone releasers such as tesamorelin, CJC-1295 and ipamorelin make the body release its own growth hormone (GH)²⁸³¹³². GH in turn raises IGF-1, a growth factor made in the liver and other tissues³¹³². In a 26-week trial in 412 patients with HIV and excess belly fat, tesamorelin raised IGF-1 by 81%³³.
• Bremelanotide (Vyleesi) acts most strongly on MC1R, found on pigment cells, and MC4R, found on nerve cells in the brain³⁰. Its action on MC1R can darken skin³⁰. Each dose raises blood pressure, by up to 6 mmHg in the top (systolic) number, peaking 2 to 4 hours later³⁰.
• Peptides sold for healing: FDA says the mechanisms of BPC-157 “remain poorly understood”³⁴. For TB-500, it says it is not yet known whether binding actin, a protein of the cell’s scaffolding, explains any healing effect³⁵.

What side effects do approved peptide drugs have?

Approved peptide drugs have side effects counted in randomized controlled trials, in which people are assigned by chance to the drug or a placebo⁶⁷.

• Semaglutide: in STEP 1, a 68-week trial in 1,961 adults funded by Novo Nordisk, nausea and diarrhea were the most common side effects⁶. They were usually mild to moderate and faded with time, but 4.5% stopped treatment because of digestive effects, versus 0.8% on placebo⁶.
• STEP UP, a 72-week trial in 1,407 adults funded by Novo Nordisk, compared weekly semaglutide doses of 7.2 mg and 2.4 mg with placebo⁸. Digestive side effects affected 70.8% on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo⁸. Dysesthesia, unusual or unpleasant skin sensations, affected 22.9%, 6.0% and 0.5%, in the same order⁸.
• The Wegovy label also warns of acute pancreatitis (an inflamed pancreas) and gallbladder disease²³. It lists kidney injury from dehydration, serious allergic reactions, diabetic eye complications and a faster heart rate too²³. In January 2026 the UK regulator strengthened its pancreatitis warnings for GLP-1 drugs, citing 1,296 pancreatitis reports from 2007 to October 2025³⁶.
• Vision: in June 2025 the EU’s medicines agency called NAION, an optic-nerve injury that can cause vision loss, a very rare semaglutide side effect³⁷. It may affect up to 1 in 10,000 people³⁷. The 2026 US labels for Wegovy, Ozempic and Rybelsus that we reviewed do not list it²³²⁶²⁷.
• Tirzepatide: in SURMOUNT-1, a 72-week trial in 2,539 adults supported by Eli Lilly, digestive side effects were the most common⁷. Most were mild to moderate and came mainly while the dose was being raised⁷. Adverse events made 4.3%, 7.1% and 6.2% stop on the 5, 10 and 15 mg doses, versus 2.6% on placebo⁷.
• Outside trials: KFF polled 1,350 US adults from 27 October to 2 November 2025⁹. Among those who had ever taken a GLP-1 drug, 13% said they had stopped because of side effects, and 14% because of cost⁹.
• Tesamorelin (Egrifta), developed by Theratechnologies: a pooled analysis of its two 26-week placebo-controlled trials covered 806 patients with HIV and excess belly fat³²³⁸. Joint pain affected 13.3% versus 11.0% on placebo, and limb swelling 6.1% versus 2.3%, in the first 26 weeks³²³⁹. Average blood sugar (HbA1c) reached the diabetes range of 6.5% or more in 5% versus 1%³².
• Bremelanotide (Vyleesi): RECONNECT, two 24-week trials in 1,267 premenopausal women funded by Palatin Technologies and AMAG Pharmaceuticals, found more nausea, flushing and headache than placebo¹⁰. Rates were 10% or more in both studies¹⁰. In the label’s Phase 3 data, 13% needed anti-nausea medicine and 8% quit because of nausea³⁰. Our women’s guide covers other risks that matter to women.

Are research peptides like BPC-157 safe?

Unapproved peptides are often sold labeled “research use only” or “not for human consumption”²⁴⁰⁴¹. A 2026 review in Missouri Medicine says BPC-157, TB-500 and melanotan II “lack established human safety profiles”¹¹.

FDA’s Category 2 list names bulk ingredients for pharmacy compounding that “may present significant safety risks”¹². On its page updated 22 April 2026, BPC-157, TB-500, CJC-1295, ipamorelin, melanotan II and injectable GHK-Cu sit on a separate list¹². They were previously in Category 2 until their nominators withdrew them, and FDA still lists its safety concerns for each¹². For outsourcing facilities (503B), ipamorelin has been in Category 2 since 29 September 2023¹²⁴². Our legal guide explains what the categories mean.

For each of them, FDA flags a possible risk of immunogenicity, an unwanted immune response to the peptide or to impurities in it⁴¹². For several, it cites aggregation, when peptide molecules clump together, or peptide-related impurities¹².

• BPC-157: the published studies FDA found gave it to fewer than 100 people, for 2 weeks or less³⁴. FDA saw safety signals in 28-day rat and dog studies, including altered blood clotting times and raised liver-related blood markers³⁴⁴³. The study authors still called it well tolerated³⁴⁴³.
• TB-500: FDA found no animal studies of its toxicity, genetic damage, effects on reproduction or cancer³⁵.
• CJC-1295: FDA lists serious adverse events “including increased heart rate and systemic vasodilatory reaction”, a body-wide widening of blood vessels¹². A trial in people with HIV, run by its developer ConjuChem, was stopped in 2006 after a participant died of a heart attack³¹. The treating doctor thought the likeliest cause was coronary artery disease that had caused no symptoms³¹. As of FDA’s 2024 review the data were unpublished, so a drug link can be neither confirmed nor ruled out³¹.
• Ipamorelin: Helsinn Therapeutics ran two Phase 2 trials that gave it by vein after bowel surgery⁴⁴⁴⁵. In the one with published results, 114 adults received it or a placebo for up to 7 days⁴⁶. Low potassium (12.5% vs 3.4%) and high blood sugar at discharge (14.3% vs 8.6%) were more common on it, and two patients on it died²⁸. FDA says it is unclear whether the deaths were related²⁸.
• Melanotan II: FDA says published case reports describe serious adverse events including melanoma, priapism and a type of brain swelling called PRES¹²⁴⁷. Priapism, an erection lasting many hours, has needed emergency drainage or surgery⁴⁸⁴⁹. Two men still had erection problems 4 and 15 weeks later⁴⁸⁴⁹.
• Injected GHK-Cu: FDA says “there are limited data in humans to inform safety-related considerations”¹². We found no published study that injected it on its own in people⁵⁰.
• MK-677 (ibutamoren), commonly used alongside injectable peptides, is not a peptide: it is a small molecule taken by mouth¹¹⁵¹. A 24-week trial in 123 hip-fracture patients stopped early after heart failure in 4 patients on it versus 1 on placebo⁵¹⁵². FDA’s 22 April 2026 page lists it in Category 2, citing “the potential for congestive heart failure in certain patients”¹².

Can peptides sold online be contaminated or fake?

Yes, and these risks come from the product rather than the peptide itself²¹¹. A 2026 review notes that online research-chemical suppliers work outside the manufacturing standards required for medicines¹¹. It says lab analyses found “significant deviations from stated dosages”, shortened peptide fragments, and heavy metals or solvent residues¹¹.

• Wrong or missing contents: WIRED bought four vials at a Brooklyn bodega, labeled PT-141, BPC-157, NAD+ and retatrutide⁵³. None contained its labeled active ingredient (reported 15 September 2026)⁵³.
• A 2023 anti-doping lab analysis of products sold online as TB500 and TB1000 found contents that did not consistently match their descriptions⁵⁴.
• Different molecules, one name: FDA has seen several salts and derivatives of BPC-157, including different active molecules, sold under the same name³⁴.
• Missing quality tests: the one certificate of analysis submitted to FDA for CJC-1295 lacked tests for impurities, aggregates and endotoxins³¹.
• Fake pens: two counterfeit tirzepatide pens detained in Ireland in 2025 held insulin instead⁵⁵. In 2023 the UK regulator reported fake Saxenda and Ozempic pens that held insulin, and some people who received them were hospitalized⁵⁶.
• Endotoxin (toxic material from bacteria): glutathione injections contaminated with it have caused fever, chills, low blood pressure and shock-like illness⁵⁷⁵⁸⁵⁹. Endotoxin exposure can also be fatal⁵⁷⁵⁹. In 2019 FDA’s lab found supplement-grade glutathione powder with endotoxin as high as five times the appropriate limit⁵⁹.
• On 1 October 2026, a Texas compounding pharmacy recalled 10 lots of glutathione because endotoxin levels might be too high⁶⁰. It also reported two patients who needed emergency care after IV use of a glutathione product not made for IV use⁶⁰.
• Sterility: in 2020 and 2021, two US firms recalled AOD-9604 vials, 3 in Indiana and 1,316 in Texas, over a lack of sterility assurance⁶¹.

These products usually come as freeze-dried powder that buyers must prepare themselves¹¹. The 2026 review says that makes bacterial endotoxin, dosing errors and injection-site infections much more likely¹¹. Our briefing on what is actually in the vials collects more lab tests.

What can go wrong with a peptide injection?

Some reactions come from the immune system: a 2025 review lists injection-site reactions, allergies, anaphylaxis (a severe whole-body allergic reaction), hypersensitivity and autoimmunity⁴. Tesamorelin’s label gives rates: in its trials, injection-site reactions affected 25% versus 14% on placebo³². Allergic reactions affected 4%, and about half of patients made antibodies against the drug³².

FAERS, FDA’s adverse event database, holds reports of harm linked to unapproved peptide products³⁴⁶². Reuters reported on 16 September 2026 that FDA data showed 10 serious adverse event reports involving BPC-157 since 2021, 8 of them in 2026⁶³. FAERS reports are unverified and cannot show which product, if any, caused an event⁶². Our blends guide covers reports that name several products.

• A US consumer report received on 19 February 2026 and marked life-threatening names a CJC-1295/ipamorelin product as the only suspect⁶². It describes a hypersensitivity reaction in a woman aged 65⁶².
• Two FAERS reports involved compounded BPC-157 injections³⁴. A woman aged 55, also injecting compounded thymosin, had 9 days of redness and swelling around the injection site³⁴. A man aged 28 had shortness of breath that led to an emergency room visit³⁴.
• A clinician who runs a wellness clinic told NPR of seeing injection-site irritation and infections in people who inject GHK-Cu⁶⁴. Some also had raised liver enzymes and copper levels, though NPR noted the cause was unclear⁶⁴.
• A woman aged 65 developed pyoderma gangrenosum, a rare ulcerating skin disease, at the sites where melanotan was injected⁶⁵. The wounds took months to heal⁶⁵.
• In July 2025, two women were hospitalized in critical condition, needing ventilators, after peptide injections at a booth at a Las Vegas festival¹³. They reported feeling as if their tongues were swelling, with trouble breathing and increased heart rates¹³. Both had received mixtures that included at least one ingredient FDA describes as posing significant risks when compounded¹³. Investigators were examining infection, contamination from the injections or a problem with the drug itself as causes (reported 29 July 2025)¹³.

Approved pens carry injection risks too: the Wegovy label warns that sharing a pen, even with a new needle, can pass on blood-borne infections²³. FDA has also received reports of adverse events, some needing hospital care, that may be linked to dosing errors with compounded semaglutide²⁹. Our briefing lists more harms reported so far.

Can peptides cause cancer or other long-term harm?

The semaglutide and tirzepatide labels carry a boxed warning about thyroid tumors seen in rodents, with the risk in people unknown²³²⁴. Both rule out use by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2²³²⁴. Studies in people taking GLP-1 drugs have reached different conclusions^14151617.

• A 2023 French study of people with type 2 diabetes compared 2,562 with thyroid cancer and 45,184 without¹⁴. Using a GLP-1 drug for 1 to 3 years was linked to a higher risk of thyroid cancer, including medullary thyroid cancer¹⁴.
• A 2024 Scandinavian study of 145,410 people who started a GLP-1 drug found no increased risk of thyroid cancer over a mean of 3.9 years¹⁵. The upper end of its estimate was consistent with “no more than a 31% increase in relative risk”¹⁵.
• A 2025 study of 98,147 GLP-1 drug users in six databases, followed for a median of 1.8 to 3.0 years, found no increased risk¹⁶. Its authors said the evidence was “insufficient to rule out excess risk with long-term use, due to the short follow-up”¹⁶.
• A 2024 meta-analysis pooled 64 randomized trials lasting at least 52 weeks¹⁷. It concluded that GLP-1 drugs “could be associated with a moderate increase in relative risk for thyroid cancer”, with a small increase in absolute risk¹⁷. It estimated that 1,349 people would need treatment for 5 years for one extra case¹⁷.

Growth hormone releasers raise a different concern, because they raise GH and, through it, the growth factor IGF-1³¹³². After 26 weeks, 47% of patients in tesamorelin’s trials had IGF-1 more than 2 standard deviations above the normal average³². European reviewers called raised IGF-1 “a major safety concern”, and the label rules out use with active cancer³²⁶⁶. In its review of MK-677, FDA notes that higher IGF-1 levels appeared to be associated with cancer risk at all ages⁵¹.

For CJC-1295, FDA found no long-term animal cancer studies, so pituitary overgrowth or tumors with long-term use cannot be ruled out³¹. The 2026 Missouri Medicine review lists long-term concerns for growth hormone stimulators¹¹. They include poor blood sugar control (glucose intolerance), fluid retention, swelling, “potential growth promotion of occult malignancy” (hidden cancers) and reduced life expectancy¹¹.

The same review lists abnormal blood vessel growth and cancer among the potential risks of unapproved peptides¹¹. BPC-157 promotes blood vessel growth in animal and cell studies, and FDA found no studies testing whether it causes cancer³⁴⁶⁷. GHK-Cu also promotes blood vessel growth in lab and animal studies, which a 2026 review says could be unwanted in tumors⁶⁸. FDA says nonclinical (lab and animal) research suggests LL-37 “can be protumorigenic”, or tumor-promoting, in some tissues¹².

A 2017 review noted four case reports of melanoma arising in existing moles after melanotan use, but said conclusive evidence of a link is lacking⁶⁹. Our melanotan II page lists the case reports.

We searched PubMed on 8 October 2026 for studies that followed people using BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu or melanotan for cancer¹⁸. We found none: the only result was a 2022 review of BPC-157 and muscle¹⁸. For these peptides, the long-term cancer risk in people is unknown¹¹¹⁸.

The evidence at a glance

A tier grades the best human evidence for any use, not whether a compound is safe. Whether each one works for the use people take it for, and its legal status: the evidence table. How we grade: our method.

Questions people ask

Go deeper

• Collagen peptides: what the trials show, and who paid for them
• Compounded semaglutide, tirzepatide and microdosing: what the evidence says
• GLP-1s and peptides before surgery, at home or in Seoul
• Peptide blends, checked against the evidence
• Peptide injection sites: what the approved labels say
• Peptide therapy, graded on the evidence
• Peptides for hair: what the trials show, and how they compare with minoxidil
• Peptides for women: what the labels and trials say
• Peptides in skincare: what the trials and labels show
• What are peptides? The science in plain English
• Every peptide, graded: the evidence table
• Best peptides for weight loss, ranked
• Best peptides for healing, ranked
• Best peptides for skin and tanning, ranked
• Best peptides for growth hormone, ranked
• Best peptides for libido, ranked
• Best peptides for longevity, ranked
• Best peptides for focus and sleep, ranked
• Best peptides for immune support, ranked
• Are peptides legal? The legal tracker
• Peptides compared, head to head
• The 2026 gray-market briefing

Sources

1. 1Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Medicine, Aug 2026. pubmed.ncbi.nlm.nih.gov
2. 2Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
3. 3Think It Through: Managing the Benefits and Risks of Medicines U.S. Food and Drug Administration, 18 Jun 2018. fda.gov
4. 4Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment Journal of Peptide Science, Jun 2025. pmc.ncbi.nlm.nih.gov
5. 5Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine, 2023. pubmed.ncbi.nlm.nih.gov
6. 6Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine, 2021. pubmed.ncbi.nlm.nih.gov
7. 7Tirzepatide Once Weekly for the Treatment of Obesity New England Journal of Medicine, 21 Jul 2022. pubmed.ncbi.nlm.nih.gov
8. 8Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial The Lancet Diabetes & Endocrinology, Nov 2025. pubmed.ncbi.nlm.nih.gov
9. 9Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford KFF, 14 Nov 2025. kff.org
10. 10Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials Obstetrics & Gynecology, Nov 2019. pubmed.ncbi.nlm.nih.gov
11. 11Dangers of Injectable Peptides and Other Unregulated “Biohacking” Drugs Missouri Medicine, 2026. pubmed.ncbi.nlm.nih.gov
12. 12Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
13. 13A Las Vegas Festival Promised Ways to Cheat Death. Two Attendees Left Fighting for Their Lives. ProPublica, 29 Jul 2025. propublica.org
14. 14GLP-1 Receptor Agonists and the Risk of Thyroid Cancer Diabetes Care, 1 Feb 2023. pubmed.ncbi.nlm.nih.gov
15. 15Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study BMJ, 10 Apr 2024. pubmed.ncbi.nlm.nih.gov
16. 16Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study Thyroid, Jan 2025. pubmed.ncbi.nlm.nih.gov
17. 17Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials Diabetes, Obesity and Metabolism, Mar 2024. pubmed.ncbi.nlm.nih.gov
18. 18PubMed search: BPC-157, TB-500, CJC-1295, ipamorelin, GHK-Cu or melanotan with cancer terms and cohort, case-control, epidemiology or follow-up terms (1 result: a 2022 review of BPC-157 and muscle) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
19. 19Anabolic Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) National Institute on Drug Abuse, 11 Jul 2024. nida.nih.gov
20. 20World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
21. 21PubMed search: peptides or growth hormone secretagogues with anabolic steroids and safety terms, limited to randomized controlled trials and comparative studies (0 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
22. 22PubMed search: BPC-157, TB-500, CJC-1295, ipamorelin, growth hormone secretagogues or peptide hormones with anabolic steroids (29 results; none compared their safety head to head in people) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
23. 23WEGOVY (semaglutide) injection and tablets: prescribing information (SPL version 19) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 30 Jun 2026. dailymed.nlm.nih.gov
24. 24ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information Eli Lilly and Company via DailyMed (U.S. National Library of Medicine), 28 Aug 2026. dailymed.nlm.nih.gov
25. 25KEGG DRUG: Semaglutide (D10025) KEGG, Kanehisa Laboratories, accessed 8 Oct 2026. kegg.jp
26. 26OZEMPIC (semaglutide) injection: prescribing information (SPL version 20) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 10 Jun 2026. dailymed.nlm.nih.gov
27. 27RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information (SPL version 14) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 19 Aug 2026. dailymed.nlm.nih.gov
28. 28FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ipamorelin-related bulk drug substances (FDA evaluation dated 19 August 2024) U.S. Food and Drug Administration, 19 Aug 2024. fda.gov
29. 29FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 1 Oct 2026. fda.gov
30. 30VYLEESI (bremelanotide injection) prescribing information Cosette Pharmaceuticals via DailyMed (U.S. National Library of Medicine), 13 Nov 2025. dailymed.nlm.nih.gov
31. 31FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: CJC-1295-related bulk drug substances U.S. Food and Drug Administration, 15 Nov 2024. fda.gov
32. 32EGRIFTA WR (tesamorelin) for injection: prescribing information (revised 3/2025) Theratechnologies via DailyMed (U.S. National Library of Medicine), Mar 2025. dailymed.nlm.nih.gov
33. 33Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 6 Dec 2007. pubmed.ncbi.nlm.nih.gov
34. 34FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
35. 35FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: TB-500-related bulk drug substances U.S. Food and Drug Administration, 15 May 2026. fda.gov
36. 36MHRA updates guidance for GLP-1 prescribers and patients Medicines and Healthcare products Regulatory Agency (GOV.UK), 29 Jan 2026. gov.uk
37. 37PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy European Medicines Agency, 6 Jun 2025. ema.europa.eu
38. 38Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data The Journal of Clinical Endocrinology & Metabolism, Sep 2010. pubmed.ncbi.nlm.nih.gov
39. 39EGRIFTA (tesamorelin for injection) prescribing information, original 2010 label U.S. Food and Drug Administration (Drugs@FDA), Nov 2010. accessdata.fda.gov
40. 40Warning letter to Royal Peptides LLC (MARCS-CMS 734884) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
41. 41Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
42. 42Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
43. 43Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Regulatory Toxicology and Pharmacology, Jul 2020. pubmed.ncbi.nlm.nih.gov
44. 44Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function (NCT01280344) ClinicalTrials.gov, 13 Apr 2017. clinicaltrials.gov
45. 45Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus (NCT00672074) ClinicalTrials.gov, 14 Apr 2017. clinicaltrials.gov
46. 46Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, Dec 2014. pubmed.ncbi.nlm.nih.gov
47. 47Melanotan and the posterior reversible encephalopathy syndrome Annals of Internal Medicine, 7 May 2013. pubmed.ncbi.nlm.nih.gov
48. 48Melanotan Tanning Injection: A Rare Cause of Priapism Sexual Medicine, Feb 2021. pubmed.ncbi.nlm.nih.gov
49. 49Melanotan-induced priapism: a hard-earned tan BMJ Case Reports, 21 Feb 2019. pubmed.ncbi.nlm.nih.gov
50. 50PubMed search: GHK-Cu or copper peptide names with injection terms (28 results; two injected people, each with a copper peptide as one ingredient of a hair-loss mixture) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
51. 51FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ibutamoren mesylate (FDA evaluation dated 3 July 2024) U.S. Food and Drug Administration, 3 Jul 2024. fda.gov
52. 52MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study Archives of Gerontology and Geriatrics, Sep 2011. pubmed.ncbi.nlm.nih.gov
53. 53Those Viral Bodega Peptides Aren’t Actually Peptides WIRED, 15 Sep 2026. wired.com
54. 54TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs Drug Testing and Analysis, Apr 2023. pubmed.ncbi.nlm.nih.gov
55. 55HPRA health warning after detention of counterfeit tirzepatide pens containing insulin Health Products Regulatory Authority (Ireland), 10 Oct 2025. hpra.ie
56. 56Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products Medicines and Healthcare products Regulatory Agency (GOV.UK), 23 Nov 2023. gov.uk
57. 57FDA reminds compounders not to use dietary supplement grade glutathione for injectables U.S. Food and Drug Administration, 27 Aug 2026. fda.gov
58. 58Drug recall enforcement reports for products described as ‘glutathione’ (openFDA query) U.S. Food and Drug Administration (openFDA), 23 Sep 2026. api.fda.gov · data query
59. 59FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables U.S. Food and Drug Administration, 7 Jun 2019. fda.gov
60. 60Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels U.S. Food and Drug Administration (company announcement), 1 Oct 2026. fda.gov
61. 61Drug recall (enforcement) reports for products described as AOD-9604, openFDA drug/enforcement API (2 records: D-0131-2021 and D-0693-2021) U.S. Food and Drug Administration (openFDA), 23 Sep 2026. api.fda.gov · data query
62. 62FDA Adverse Event Reporting System (FAERS) reports naming ipamorelin, retrieved via the openFDA drug/event API U.S. Food and Drug Administration (openFDA), 30 Jul 2026. api.fda.gov · data query
63. 63Use of experimental ‘Wolverine’ peptide backed by RFK Jr is on the rise, study finds The Independent (Reuters), 16 Sep 2026. independent.co.uk
64. 64The copper peptide trend has gone from creams to injections — ahead of the science NPR, 7 Sep 2026. npr.org
65. 65Pyoderma Gangrenosum Secondary to Melanotan Cureus, Dec 2025. pubmed.ncbi.nlm.nih.gov
66. 66Egrifta: withdrawal of the marketing authorisation application (questions and answers, EMA/CHMP/475021/2012) European Medicines Agency, 18 Jul 2012. ema.europa.eu
67. 67Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of Molecular Medicine, Mar 2017. pubmed.ncbi.nlm.nih.gov
68. 68GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap Pharmaceutics, 27 Aug 2026. pmc.ncbi.nlm.nih.gov
69. 69Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review International Journal of Dermatology, Oct 2017. pubmed.ncbi.nlm.nih.gov
70. 70SAXENDA (liraglutide) injection: prescribing information (SPL version 22) Novo Nordisk via DailyMed (U.S. National Library of Medicine), 15 Jun 2026. dailymed.nlm.nih.gov
71. 71We’d Rather Buy the Future Than Wait For It Finnrick, 10 Jun 2026. finnrick.com